Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)

被引:26
|
作者
Palte, Rachel L. [1 ]
Schneider, Sebastian E. [1 ]
Altman, Michael D. [1 ]
Hayes, Robert P. [2 ]
Kawamura, Shuhei [1 ]
Lacey, Brian M. [1 ]
Mansueto, My Sam [1 ]
Reutershan, Michael [1 ]
Siliphaivanh, Phieng [1 ]
Sondey, Christopher [1 ]
Xu, Haiyan [1 ]
Xu, Zangwei [1 ]
Ye, Yingchun [1 ]
Machacek, Michelle R. [1 ]
机构
[1] Merck & Co Inc, Computat & Struct Chem, Boston, MA 02115 USA
[2] Computat & Struct Chem, West Point, PA 19486 USA
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 09期
关键词
PRMT5; allosteric inhibition; methyltransferase; peptide competitive; SAM competitive; crystal structure; SELECTIVE INHIBITOR; METHYLATION; POTENT; DISCOVERY; DELETION; HISTONE;
D O I
10.1021/acsmedchemlett.9b00525
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Protein arginine methyltransferase 5 (PRMT5) belongs to a family of enzymes that regulate the posttranslational modification of histones and other proteins via methylation of arginine. Methylation of histones is linked to an increase in transcription and regulates a manifold of functions such as signal transduction and transcriptional regulation. PRMT5 has been shown to be upregulated in the tumor environment of several cancer types, and the inhibition of PRMT5 activity was identified as a potential way to reduce tumor growth. Previously, four different modes of PRMT5 inhibition were known-competing (covalently or non-covalently) with the essential cofactor Sadenosyl methionine (SAM), blocking the substrate binding pocket, or blocking both simultaneously. Herein we describe an unprecedented conformation of PRMT5 in which the formation of an allosteric binding pocket abrogates the enzyme's canonical binding site and present the discovery of potent small molecule allosteric PRMT5 inhibitors.
引用
收藏
页码:1688 / 1693
页数:6
相关论文
共 50 条
  • [41] Effects of substrate modifications on the arginine dimethylation activities of PRMT1 and PRMT5
    Fulton, Melody D.
    Dang, Tran
    Brown, Tyler
    Zheng, Y. George
    EPIGENETICS, 2022, 17 (01) : 1 - 18
  • [42] Prmt5 promotes vascular morphogenesis independently of its methyltransferase activity
    Quillien, Aurelie
    Gilbert, Guerric
    Boulet, Manon
    Ethuin, Severine
    Waltzer, Lucas
    Vandel, Laurence
    PLOS GENETICS, 2021, 17 (06):
  • [43] The protein arginine methyltransferase PRMT5 regulates A-induced toxicity in human cells and Caenorhabditis elegans models of Alzheimer's disease
    Quan, Xin
    Yue, Wenhui
    Luo, Yunfeng
    Cao, Jianwei
    Wang, Hongyun
    Wang, Yue
    Lu, Zhongbing
    JOURNAL OF NEUROCHEMISTRY, 2015, 134 (05) : 969 - 977
  • [44] Glutathionylation Decreases Methyltransferase Activity of PRMT5 and Inhibits Cell Proliferation
    Yi, Meiqi
    Ma, Yingying
    Chen, Yuling
    Liu, Chongdong
    Wang, Qingtao
    Deng, Haiteng
    MOLECULAR & CELLULAR PROTEOMICS, 2020, 19 (11) : 1910 - 1920
  • [45] Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5
    Zhang, Baolai
    Zhang, Su
    Zhu, Lijuan
    Chen, Xue
    Zhao, Yunfeng
    Chao, Li
    Zhou, Juanping
    Wang, Xing
    Zhang, Xinyang
    Ma, Nengqian
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 336 : 1 - 7
  • [46] Discovery and Biological Characterization of PRMT5:MEP50 Protein-Protein Interaction Inhibitors
    Asberry, Andrew M.
    Cai, Xinpei
    Deng, Xuehong
    Santiago, Ulises
    Liu, Sheng
    Sims, Hunter S.
    Liang, Weida
    Xu, Xueyong
    Wan, Jun
    Jiang, Wen
    Camacho, Carlos J.
    Dai, Mingji
    Hu, Chang-Deng
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (20) : 13793 - 13812
  • [47] The expression of myogenic microRNAs indirectly requires protein arginine methyltransferase (Prmt)5 but directly requires Prmt4
    Mallappa, Chandrashekara
    Hu, Yu-Jie
    Shamulailatpam, Priscilla
    Tae, Sookil
    Sif, Said
    Imbalzano, Anthony N.
    NUCLEIC ACIDS RESEARCH, 2011, 39 (04) : 1243 - 1255
  • [48] Discovery of novel PRMT5 inhibitors bearing a methylpiperazinyl moiety
    Bai, Xinyu
    Zhai, Zheng
    Zhao, Xuyang
    Li, Ridong
    Liang, Ling
    Jin, Yan
    Yin, Yuxin
    FUTURE MEDICINAL CHEMISTRY, 2022, 14 (14) : 1071 - 1086
  • [49] OXR1A, a Coactivator of PRMT5 Regulating Histone Arginine Methylation
    Yang, Mingyi
    Lin, Xiaolin
    Segers, Filip
    Suganthan, Rajikala
    Hildrestrand, Gunn A.
    Rinholm, Johanne E.
    Aas, Per Arne
    Sousa, Mirta M. L.
    Holm, Sverre
    Bolstad, Nils
    Warren, David
    Berge, Rolf K.
    Johansen, Rune F.
    Yndestad, Arne
    Kristiansen, Elise
    Klungland, Arne
    Luna, Luisa
    Eide, Lars
    Halvorsen, Bente
    Aukrust, Pal
    Bjoras, Magnar
    CELL REPORTS, 2020, 30 (12): : 4165 - +
  • [50] PRMT5 as a druggable target for glioblastoma therapy
    Banasavadi-Siddegowda, Yeshavanth Kumar
    Welker, Alessandra M.
    An, Min
    Yang, Xiaozhi
    Zhou, Wei
    Shi, Guqin
    Imitola, Jaime
    Li, Chenglong
    Hsu, Sigmund
    Wang, Jiang
    Phelps, Mitch
    Zhang, Jianying
    Beattie, Christine E.
    Baiocchi, Robert
    Kaur, Balveen
    NEURO-ONCOLOGY, 2018, 20 (06) : 753 - 763